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Hepatocellular carcinoma (HCC) is the sixth 
most common cancer and the second leading cause 
of cancer-related mortality worldwide6,9). Advances 
in biotechnology have made it possible to develop 
new diagnostic techniques, such as ultrasonogra-
phy, computed tomography (CT), magnetic reso-
nance imaging (MRI), and angiography. Similarly, 
new treatment modalities have been invented, 
such as surgical resection, radiofrequency ablation 
(RFA), percutaneous ethanol injection (PEI), 
transcatheter arterial chemoembolization (TACE), 
and hepatic arterial infusion chemotherapy 
(HAIC), which have improved the prognosis of 
HCC patients1,3,4,7,8,14,15,23,25). However, the survival 
rates of patients with advanced HCC and associat-
ed complications such as portal vein tumor throm-
bosis (PVTT), venous tumor thrombosis (VTT), 
and refractoriness to TACE, have not improved 
enough. 
Two phase III clinical trials of sorafenib for ad-
vanced HCC showed significant efficacy in terms of 
overall survival time (OST) compared with a place-
bo 2,6). Based on these studies, sorafenib has become 
the standard therapy for advanced HCC. Sorafenib 
contributed to prolonging OST by 2.3-2.8 months and 
the response rate (RR) by 2.0-3.3%. However, the sur-
vival advantage of sorafenib is described as insuffi-
cient. 
HAIC is widely undergone in Asia, especially Ja-
pan. Several studies have shown the survival benefits 
of HAIC for advanced HCC free of extrahepatic me-
tastasis, with a response rate ranging from 20.8 to 
52%, and have reported that median survival time 
(MST) in responders is 17.6-40.7 months1,11,19,23,27,28). 
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ABSTRACT
To assess the outcome of stable disease (SD) patients with advanced hepatocellular carcinoma 
(HCC) by tumor markers after the first course of hepatic arterial infusion chemotherapy (HAIC). 
The study subjects were 156 HCC patients treated with HAIC and classified as Child Pugh A, 
with no extrahepatic metastasis, and no history of sorafenib treatment. In the study and 
validation cohorts, the AFP and DCP ratios of patients who were considered SD to the first 
course of HAIC were analyzed by AUROC for a prediction of response to the second course of 
HAIC. The imaging response to the first course of HAIC was classified as partial response (PR), 
SD and progressive disease (PD) in 29 (18.8%), 80 (51.9%), and 44 (28.6%) patients respectively. 
For SD patients, the α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) ratios of patients 
who were considered SD to the first course of HAIC were analyzed by the receiver operating 
characteristic curve for prediction of response to the second course of HAIC in the study cohorts. 
The area under the curve of AFP ratio was 0.743. The area under the curve of DCP ratio was 
0.695. The cut-off values of AFP and DCP ratios were 1.3 and 1.0, respectively. In the validation 
cohort, the accuracy of the prediction of response in this validation cohort (71.4%) showed no 
significant difference compared to that in the study cohort (72.4%) (p = 1.0). The results 
suggested that patients with a high tumor marker ratio could be switched to alternative 
therapeutic regimens despite the SD response to HAIC.
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neous interferon (5FU+IFN). One course of chemo-
therapy was undergone for 2 weeks. 5FU (300 mg 
body weight/day) was administered over 24 hr by 
using a mechanical infusion pump from days 1 to 
5 of the first and second weeks in both regimens. 
CDDP was injected intra-arterially via a pump at 
6 mg/body weight/day on days 1-5 and 8-12. The 
IFN in the 5FU+IFN regimen was recombinant 
IFNα-2b [Intron A, Schering-Plough Pharmaceuti-
cals, Osaka, Japan, 3 × 106 U (3 MU)], or natural 
IFN-α [OIF, Otsuka Pharmaceuticals, Tokyo, 5 × 
106 U (5 MU)] administered intramuscularly on 
days 1, 3, and 5 of each week (total dose, 36 and 
60 MU, respectively). We reported previously that 
recombinant IFNα-2b had an equal effect to natu-
ral IFN-α when the combination of 5FU+IFN was 
used for the treatment of advanced HCC28).  
Assessment of response to HAIC.  Each patient 
underwent dynamic CT before HAIC and also af-
ter each course of HAIC. In this study, we defined 
the terms imaging response and AFP/DCP tumor 
marker response. The imaging response to HAIC 
was evaluated by RECIST (version 1.1) on dynam-
ic CT after the first course of HAIC (4 weeks lat-
er). A complete response (CR) was defined as the 
disappearance of all target lesions after one course 
of HAIC. A partial response (PR) was defined as 
the sum of the longest diameter reducing by more 
than at least 30% compared to before HAIC. Pro-
gressive disease (PD) was defined as the sum of 
the longest diameter of the target lesion increas-
ing more than at least 20%. Stable disease (SD) 
was defined as corresponding neither to the crite-
ria of PR nor PD. HAIC was continued repeatedly 
as long as the treatment response was better than 
SD. To evaluate the AFP/DCP tumor marker re-
sponse, we measured these markers from the se-
rum concentrations after each course of HAIC 
(each 4 weeks). In our hospital, the normal range 
of AFP is within 10 ng/ml, while that of DCP is 
within 30 mAU/ml. The AFP ratio represented the 
AFP value after one course of HAIC divided by 
the AFP value before treatment. The DCP ratio 
was measured similarly. When both tumor mark-
However, large randomized trials are not demonstrat-
ed efficiently. In most of the retrospective studies, sur-
vival time was much longer in responders than in 
non-responders. We have reported that survival after 
switching HAIC treatment to sorafenib was better 
than that of continuous HAIC20). At present, however, 
there is no biomarker that can be used to predict the 
response to HAIC treatment. Such a marker could 
help in decision making on whether to continue HAIC 
treatment or not.
The treatment response to HCC is assessed by 
imaging studies. One of the most common methods 
for response evaluation is the Response Evalua-
tion Criteria in Solid Tumors (RECIST) 5). Howev-
er, it is inefficient to evaluate response to the first 
course of treatment by imaging studies alone. On 
the other hand, some studies have shown the use-
fulness of a-fetoprotein (AFP) and des-γ-carboxy 
prothrombin (DCP) not only as tumor markers, 
but also as prognostic factors for HCC13,17,22,26). We 
reported that patients with AFP and DCP ratios 
of >1 had significantly poorer survival than others 
(MST 7.4 vs 12.6 months, p=0.014), among pa-
tients with stable disease (SD) based on imaging 
response to first course of chemotherapy21). To our 
knowledge, there are no clear cut-off values for 
AFP ratio and DCP ratio.
The present retrospective study was designed to 
analyze the cut-off values of the AFP and DCP ra-
tios for outcome to the first course of chemotherapy 
in HCC patients with SD.
MATERIALS AND METHODS
Patients.  Between June 2000 and March 2015, 
364 patients with unresectable HCC were treated 
with HAIC at our hospital. HAIC was selected as 
the therapeutic option for patients with advanced 
HCC who presented also with PVTT and VTT, 
and refractoriness to TACE. We excluded the fol-
lowing patients from HAIC: 1) The performance 
status of the Eastern Cooperative Oncology Group 
(ECOG) was ≥3 (n=1). 2) Child–Pugh score of ≥7 
(n=109), 3) extrahepatic metastasis (n=80), 4) 
treatment with sorafenib before and after HAIC 
(n=18). After the exclusion of the above 208 pa-
tients, the remaining 156 patients were enrolled 
in this retrospective cohort study (Fig. 1). The 
study protocol was approved by the Human Ethics 
Review Committee of Hiroshima University and a 
signed consent form was obtained from each sub-
ject.  
Hepatic arterial infusion chemotherapy (HAIC). 
Patients were given arterial infusions of antican-
cer agents via the injection port. Two drug regi-
mens are used in HAIC. We used intra-arterial 
low-dose cisplatin (CDDP, Nihonkayaku, Tokyo, 
Japan) with 5- fluorouracil (5FU, Kyowa Hakko, 
Tokyo) (FP), or intra-arterial 5FU with subcuta-
364 patients treated with HAIC
Between June 2000 and March 2015
Child–Pugh score of ≥7 (n=109) 
treatment with sorafenib before and after HAIC 
(n=18)
extrahepatic metastasis (n=80)
Child pugh score 5,6 and  no extra hepatic metastasis
156 patients
Child–Pugh score 5,6
254 patients 
PS 3 (n=1) 
Fig. 1. Patient recruitment process
27Response to Arterial Chemotherapy by Tumor Markers
mulative survival rate was calculated from the 
date of initiation of HAIC, assessed by the Kaplan-
Meier life-table method, and differences between 
groups were evaluated by the log rank test. Uni-
variate analysis of the factors that correlated with 
survival of patients with HCC treated with HAIC 
was assessed by the Kaplan-Meier life-table meth-
od, and differences were evaluated by the log rank 
test. Multivariate analysis of the factors that in-
fluenced survival was assessed by the Cox propor-
tional hazard model. Statistical significance was 
defined as p value of less than 0.05. 
Cut-off points for continuous variables were de-
termined by analysis of the receiver operating 
characteristic (ROC) curve based on the minimum 
balanced error rate (BER)18). BER is the average 
of the proportion of incorrect classifications in 
each class. 
The cut-off value associated with maximum ac-
curacy, sensitivity, and negative and positive pre-
dictive values of the PD to the second course of 
treatment was computed. The chi-squared test 
was used to compare the accuracy of the predic-
tion score in the study cohort with that of the vali-
dation cohort. 
 All analyses described above were performed 
with The Statistical Package for Social Sciences 
software (version 11, SPSS, Chicago, IL).
RESULTS
Baseline characteristics.  Patient characteristics 
are listed in Table 1. The study subjects were 140 
men and 16 women, and the median age was 68 
ers were within the normal range before and after 
treatment, the tumor marker ratio was ≤ 1.
Adverse drug reactions were defined according 
to the Common Terminology Criteria for Adverse 
Events version 4.0.
Follow-up and other therapies.  Treatment with 
sorafenib was not administered throughout the 
clinical course. Instead, other therapies such as 
RFA, TACE and radiotherapy were used for par-
tial and non-responders. PR patients continued to 
receive HAIC regularly in combination with other 
therapies. Patients whose advanced HCC was 
down-staged to a single tumor ≤ 50 mm in diame-
ter or 1-3 tumors each ≤ 30 mm in diameter fol-
lowing the combination therapy, were considered 
to receive RFA or hepatectomy. In addition to 
HAIC, PD patients received TACE. TACE was 
used after HAIC in the following situations: 1) ad-
ditional TACE aimed at downstaging HCC when 
patients showed an effective response to HAIC, 
and 2) palliative TACE aimed to prevent HCC 
rupture or rapid growth when patients showed 
non-response to HAIC. PD patients were also con-
sidered for radiotherapy when complicated with 
portal venous tumor thrombosis (PVTT). For CR 
patients, the clinical course was observed without 
adjuvant chemotherapy or additional therapy.
Statistical analysis. Statistical analysis was 
performed in August 2015. Differences between 
groups were examined for statistical significance 
using the Mann-Whitney U test, logistic regres-
sion test, or squared test, as appropriate. The cu-
Table 1. Clinical characteristics of HCC patients treated with HAIC (n=156)
Age (years) * 68.0 (32-85)
Gender (M/F) 140/16 
ECOG performance status (0/1/2) 133/21/2 
Child-Pugh score (5/6) 84/72
Etiology (HBV/HCV/others) 42/85/29
Number of HCC tumors (solitary/multiple) 22/134
Size of liver tumor (mm) * 60 (10-180)
HCC stage (II/III/IVa) † 4/49/103 
Vp (0/1/2/3/4) § 49/6/24/44/33
Vv (0/1/2/3) ‡ 132/1/10/13 
Relative tumor size in the liver (<50%/≥50%) 117/39 
Platelet count (/mm3) * 12 (4.6-88.8)
AFP (ng/ml) * 464 (2.9-1895000)
DCP (mAU/ml) * 1733 (7-666480)
HAIC regimen (FP/5FU+IFN) 86/70
*Data are median and (range) values, or number of patients.
†According to the Liver Cancer Group of Japan. 
§Portal invasion. ‡Venous invasion. 
CP: Child Pugh, ECOG: Eastern Cooperative Oncology Group, HCV: hepatitis C virus, HBV: hepatitis B virus, HCC: 
hepatocellular carcinoma, Vp2: tumor thrombus in the second branch of the portal vein, Vp3: tumor thrombus in the first branch 
of the portal vein, Vp4: tumor thrombus in the trunk of the portal vein, Vv2: tumor thrombus in the right, middle or left hepatic 
vein trunk, posterior inferior hepatic vein trunk or short hepatic vein, Vv3: tumor thrombus in inferior vena cava, AFP: 
α-fetoprotein, DCP: des-γ-carboxy prothrombin, FP: intra-arterial low-dose cisplatin and 5FU therapy, 5FU+IFN: intra-arterial 
5-FU with IFN combination therapy.
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tors that could stratify the survival of SD patients 
to the first course of HAIC. In the median survival 
time of HAIC, there is no significant difference be-
tween FP (MST 11 months) and 5FU+IFN (MST 
10 months) (p=0.8).
Background of SD patients by imaging response 
to first course.  Table 2 lists the background of SD 
patients according to imaging response to the first 
course of HAIC. Among the 156 patients, 80 pa-
tients were classified as SD by the imaging re-
sponse. 
With regard to AFP and DCP, 23 patients who 
were treated with warfarin or vitamin K were 
excluded from analysis. Of the remaining 57 pa-
tients, 54 were men and 3 were women, with a 
median age of 68 years. The background liver dis-
ease was HCV infection in 36 and other diseases 
in 21. The Child-Pugh score was 5 in 28 patients 
and 6 in 29 patients. HCC was classified as stage 
II, III, and IVa in 1, 17, and 39 patients, respec-
tively. In this group, the median value of AFP ra-
tio was 1.27 while that of DCP ratio was 0.99. For 
the study cohort, data from 28 consecutive pa-
tients who were treated between 2000 and 2007 
with HAIC were collected. Data from 29 patients 
treated between 2007 and 2015 were also collected 
as an independent validation cohort (Table 3). 
There was no significant difference between study 
cohort and validation cohort in their background.
Imaging response to second course of HAIC 
and overall survival among SD patients to first 
course of HAIC.  Patients who were considered 
SD to the first course of HAIC were assessed 
again by CT after the second course of HAIC. One 
(1.65%) patient was classified as CR, 11 (17.7%) as 
PR, 27 (43.5%) as SD and 23 (37.1%) patients as 
years. The Child-Pugh score was 5 points in 84 
patients and 6 points in 72 patients. The back-
ground liver disease was hepatitis C viral (HCV) 
infection in 85 patients, hepatitis B viral (HBV) 
infection in 42, and non-HCV-non-HBV in 29. Soli-
tary HCC was detected in 22 patients and multiple 
HCCs in 134. HCC was classified as stage II, III 
and IVa in 4, 49 and 103 patients, respectively. 
Portal venous invasion was identified in 107 pa-
tients and venous invasion in 24 patients. The me-
dian value of AFP was 464 ng/ml and that of DCP 
was 1733 mAU/ml.
Imaging response after first course of HAIC 
and overall survival.  Imaging response by RE-
CIST to the first course of treatment was CR in 
one (0.6%) patient, PR in 29 (18.8%), SD in 80 
(51.9%) and PD in 44 (28.6%) patients. MST var-
ied significantly among the Imaging response 
groups (p < 0.0001) and was 26.6, 12.2 and 5.5 
months in the PR, SD and PD groups, respectively 
(Fig. 2). The percentage of SD patients was more 
than 50%, and accordingly we examined the fac-
Table 2. Background of SD patients (n=57) according to the imaging response to 
the first course of chemotherapy
Age (years) * 68 （34-85）
Gender (M/F) 54/3
ECOG performance status (0/1) 50/7
Child-Pugh score (5/6) 28/29
Etiology (HBV/HCV/others) 13/36/8
Number of HCC tumors 4 (1-100)
Size of liver tumor (mm) * 69 (10-180)
HCC stage (II/III/IVa) † 1/17/39 
Vp (0-2/3-4) § 31/26
Vv (0-1/2-3) ‡ 50/7
Relative tumor size in the liver (<50%/≥50%) 42/15
Platelet count (/mm3) * 12.2 (5.1-49.8)
AFP (ng/ml) * 387.3 (2.9-869800)
DCP (mAU/ml) * 1512 (10-120070)
AFP ratio * 1.27 (0.02-29.3)
DCP ratio * 0.99 (0.008-12.4)
Regimen (IFN+5FU/CDDP+5FU) 22/35
For abbreviations see Table 1.
p<0.0001
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Fig. 2. Cumulative survival rates according to 
imaging response to the first course of HAIC
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and specificity of 58.8%. The area under the curve 
of the DCP ratio was 0.695, with a sensitivity of 
63.6% and specificity of 58.8%. The cut-off values 
of the AFP and DCP ratios were 1.3 and 1.0, re-
spectively. That is, AFP ratio >1.3 and DCP ratio 
>1.0 were defined as a prediction of PD to the sec-
ond course. We next evaluated the accuracy of the 
prediction score using an independent validation 
cohort consisting of 29 patients. The positive pre-
dictive value (PPV) and negative predictive value 
(NPV) for PD were 66.7% and 73.6% in the study 
cohort. On the other hand, the PPV and NPV for 
PD were 75.0% and 72.0% in the study cohort.
The accuracy of the prediction of response in 
this validation cohort (71.4%) showed no signifi-
cant difference compared to that in the study co-
hort (72.4%) (p=1.0, Fig. 4). 
PD. Among the SD patients to the first course 
HAIC and MST varied significantly (p < 0.0001) 
and were 32.1, 13.3 and 6.9 months in the PR, SD 
and PD groups, respectively. 
Prediction of response to the second course 
of HAIC in the study and validation cohorts. 
First, the AFP and DCP ratios of patients who 
were considered SD to the first course of HAIC 
were analyzed by ROC for prediction of response 
to the second course of HAIC in the study cohort 
(Fig. 3). The sensitivities and specificities of the 
AFP and DCP ratios among these patients are 
shown in Figs. 3a and b. The area under the curve 
of AFP ratio was 0.743, with a sensitivity of 81.8% 
Table 3. Background of SD patients (n=57) according to the imaging response to the first course of 
chemotherapy in the study cohort and the validation cohort 
Study cohort（n=28） validation cohort（n=29） p value
Characteristics 　 　 　
Age (years) *  67.0 (45-85)  75 (34-84) 0.506
Gender (M/F)  26/2  28/1 0.532
ECOG performance status (0/1)  25/3  25/4 0.723
Child-Pugh score (5/6)  11/17  17/12 0.144
Etiology (HBV/HCV/others)  4/21/3  9/15/5 0.182
Number of liver tumors *  6 (1-40)  5 (1-20) 0.435
Size of liver tumors (mm) *  50 (18-105)  80 (21-180) 0.089
HCC stage (II/III/IVa) †  1/7/20  0/10/19 0.487
Vp (0-2/3-4) §  15/13  16/13 0.903
Vv (0-1/2-3) ‡  25/3  25/4 0.723
Relative tumor size in the liver   
 (<50%/>50%)  20/8  22/7 0.704
Platelet count (/mm3) *  10.3 (5.1-49.8)  14.8 (6.1-39.5) 0.143
AFP (ng/ml) *  905 (10-394000)  332 (2.9-869800) 0.893
DCP (mAU/ml) *  1702 (10-120070)  2868 (41-102590) 0.893
HAIC regimen (FP/5FU+IFN)  11/17  11/18 0.916
Response to the first course
 (CR/PR/SD/PD) 1/8/8/11 0/2/17/10 0.021
For abbreviations see Table 1.
Fig. 3. Area under the receiver operating characteristics 
curve for (a) AFP ratio and (b) DCP ratio among SD 
patients to the first course of HAIC in study cohort. 
The cut-off value associated with maximum accuracy, 
sensitivity, and negative and positive predictive values 
of the PD to the second course of treatment was com-
puted.
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Fig. 4. The accuracy of the prediction of response to the 
second course of HAIC in study and validation cohort
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and DCP ratio of > 1, and others. SD patients with 
AFP ratio of > 1.3 and DCP ratio of > 1 had a sig-
nificantly poorer survival than others (MST 7.5 vs 
13.3 months, p=0.027, Fig. 5). These results indi-
cated that the cut-off values of AFP and DCP ra-
tios could be used to predict the overall survival 
after the second course of HAIC in SD patients to 
the first course.
DISCUSSION
The response to HCC treatment is assessed ac-
cording to RECIST or mRECIST with imaging 
modalities. In clinical practice, there is no bio-
marker that can be used to predict the response to 
HAIC and, accordingly, there are no criteria that 
can be used for continuation or discontinuation of 
HAIC. Patients who show a CR or PR response 
should continue HAIC while those who show PD 
should be switched to other treatments including 
sorafenib. However, in our hospital, the number of 
patients who showed a SD response was more 
than half of all patients. For this reason, we ana-
lyzed their data to identify HCC tumor markers 
that could predict overall survival. The results 
showed that patients with the combination of an 
AFP ratio of > 1.3 and a DCP ratio of > 1 had sig-
nificantly poorer survival than others among SD 
patients to the first course of HAIC. 
Previous studies analyzed the prognosis of HCC 
patients treated with HAIC using RECIST or 
mRECIST with imaging modalities, which is re-
garded as the gold standard for evaluation of thera-
peutic response. Sorafenib was introduced recently 
as a molecular targeting therapy for advanced 
HCC, though there are no guidelines for assess-
ment of the response to such treatment. In the 
present study, we analyzed first the treatment re-
sponse to the first course of HAIC by the combina-
tion of RECIST and tumor marker ratios. We also 
analyzed the data for whether the response to the 
first course of HAIC can be used to predict the 
prognosis of patients. The results showed that the 
Multivariate analysis of factors contributing 
to overall survival in SD patients by imaging 
response to first course.  Univariate analysis 
was used to investigate the relationship between 
overall survival of patients who were considered 
SD to the first course of HAIC. Overall survival 
correlated significantly with etiology (p=0.05), 
AFP ratio > 1.3 and DCP ratio > 1.0 (p=0.0025), 
and tumor size relative to liver size (p=0.005). In-
clusion of the above factors in multivariate analy-
sis showed that an AFP ratio > 1.3 and DCP ratio 
> 1.0 was the only determinant of overall survival 
in patients considered SD to the first course of 
HAIC (p=0.035: hazard ratio 2.012, 95%CI 1.36-
3.907) (Table 4). 
Overall survival according to AFP and DCP 
ratios among SD patients to first course of 
HAIC.  The MST of SD patients with AFP ratio of 
≤ 1.3 and DCP ratio of ≤ 1, > 1.3 and ≤ 1, ≤ 1.3 and 
> 1, and > 1.3 and > 1 were 13.3, 12.1, 13.6 and 7.5 
months, respectively (p=0.067). We also divided 
the patients into two groups: AFP ratio of > 1.3 
Fig. 5. Overall survival among SD patients to the first 
course of HAIC, according to tumor markers.
Solid line: patients with AFP ratio > 1.3 and DCP ratio 
> 1.
Dotted line: others.
p=0.027
AFP ratio>1.3 and DCP ratio>1.0
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Table 4. Results of multivariate analysis of determinants of survival in SD patients to the first course of HAIC
Parameters
Univariate analysis Multivariate analysis
p value Hazard ratio 95% CI p value
All patients
Age (<65/≥65 years) 0.894
Gender (M/F) 0.454
Etiology (HCV/others) 0.05
AFP ratio >1.3 and DCP ratio >1.0/others 0.0025 2.012 1.36-3.907 0.035
Relative size of liver tumor (50%/≥50%) 0.005
Vascular invasion (positive/negative) 0.903
Number of liver tumors (single/multiple) 0.649
Size of liver tumor (<50 mm/≥50 mm) 0.24
TACE refractoriness (presence/absence) 0.228
Regimen (IFN+5FU/CDDP+5FU) 0.176
For abbreviations see Table 1.
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the exception of tumor markers. In comparison, our 
study was limited to tumor markers, excluded pa-
tients treated with sorafenib before and after 
HAIC, extrahepatic metastasis and Child-Pugh B, 
and thus allowed us to study the prognosis of pa-
tients treated by HAIC.
Sorafenib is currently the standard treatment 
for advanced HCC patients. In two randomized 
studies, placebo-control led cl inical tr ials, 
sorafenib extended overall survival by 2.3-2.8 
months and the response rate by 2.0-3.3%2,16). Al-
though the effectiveness of HAIC for advanced 
HCC has been reported in some reports, large 
randomized trials are lacking. To our knowledge, 
there is no defined strategy for the standard of 
treatment with sorafenib and HAIC for advanced 
HCC patients. We think that it is important to 
pick up responders to HAIC as early as possible. 
In other words, HAIC must be switched to 
sorafenib as early as possible for PD patients of 
HAIC. Therefore, in this study, the patients were 
limited to Child-Pugh A patients who could be 
treated with sorafenib. The efficacy of sorafenib 
and HAIC on advanced HCC are currently being 
assessed in a few clinical trials in Japan. We are cur-
rently conducting an ongoing HICS study (pilot 
study of HAIC followed by sorafenib for advanced 
HCC, UMIN#000009094). Another Japanese clin-
ical study based on the same purpose (HAIC fol-
lowed by sorafenib) is ongoing: the SCOOP-II trial 
(Sequential hepatic arterial infusion chemothera-
py with cisplatin followed by sorafenib versus 
sorafenib alone in advanced hepatocellular carci-
noma, UMIN#000006147). These studies are de-
signed to pick up refractoriness to HAIC using the 
combination of imaging response and tumor mark-
er response after every course of therapy. 
The present study has certain limitations. First, 
it was a retrospective cohort study that examined 
a small population. A prospective study of a larger 
patient population is needed to confirm the find-
ings. Second, various chemotherapeutic regimens 
were used in the study population. However, previ-
ous studies showed no significant differences in 
response or survival among these regimens21). A 
validation study of HCC patients treated with a 
single regimen is required. 
In conclusion, we used RECIST to evaluate the 
response of SD patients to the first course of HAIC 
and demonstrated that the combination of AFP ra-
tio of > 1.3 and DCP ratio of > 1 could be used to 
predict the prognosis of patients with advanced 
HCC. The results emphasize the need to switch to 
alternative therapies in patients with a high tu-
mor marker ratio despite SD response to HAIC.
(Received April 5, 2016)
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AFP and DCP ratio can be used to determine treat-
ment selection; i.e., continuation or change from 
HAIC. We reported previously that the survival of 
patients with AFP and DCP ratios of > 1 was sig-
nificantly poorer and that the response did not 
change to CR or PR during the course of treatment 
in SD patients21). However, the cut-off values of 
AFP and DCP were decided without statistics. That 
is, we decided the cut-off values of AFP and DCP 
by only the elevation after treatment. As a result, 
we decided the cut-off values of AFP and DCP by 
ROC analysis in the present study. Furthermore, in 
order to confirm that the cut-off values were appro-
priate, we studied the cut-off values of AFP and 
DCP by study cohort and validation cohort in the 
present study. Therefore, the present study deter-
mined the cut-off values of AFP and DCP ratios by 
statistics. Based on the imaging responses to the 
second course of HAIC, the median survival time 
was 6.9 months in the PD groups. Therefore, we 
used ROC analysis to determine the cut-off values 
that were associated with the highest accuracy, 
sensitivity, and negative and positive predictive 
values of PD to the second course of HAIC. The 
results showed that the best cut-off values were 1.3 
for the AFP ratio and 1.0 for the DCP ratio in the 
study cohort. We next evaluated the accuracy of 
the prediction response using an independent vali-
dation cohort consisting of 29 patients. The accu-
racy of the prediction of response in this validation 
cohort (71.4%) was not significantly different com-
pared to that in the study cohort (72.4%) (p=1.0). 
Further analysis showed that patients with an 
AFP ratio of > 1.3 and DCP ratio of > 1 had signif-
icantly poorer survival than others (MST 7.5 vs 
13.3 months, p=0.027), indicating that the tumor 
marker response can accurately predict refractori-
ness to HAIC.
Saeki et al 24) categorized their patients according 
to Child-Pugh, AFP and DCP responses after a 
half course of HAIC (2 weeks) and showed signifi-
cantly different prognoses. However, they defined 
AFP- or DCP-positive-response as a reduction in se-
rum AFP or DCP of more than 20% from baseline 
after half a course of HAIC. However, no reason 
was given for the selection of 20% reduction. It is 
possible that some patients showed a good overall 
survival despite a less than 20% reduction in se-
rum AFP or DCP after a half course of HAIC. In 
our study, none of the patients who showed PR or 
CR in the second course had a AFP ratio of > 1.3 
and DCP ratio of > 1 because the cut-off was deter-
mined by ROC analysis. Furthermore, the study of 
Saeki et al 24) included patients with extrahepatic 
metastasis and classified it as Child-Pugh B. It is 
reported that patients with extrahepatic metasta-
ses treated with HAIC show poor overall surviv-
al10). Furthermore, overall survival is also poor in 
Child-Pugh B patients treated with sorafenib12). 
Thus, the above study included many biases with 
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